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Bilirubin, the product of heme catabolism, 
represents an important endobiotic of the 
endo-and xenobiotic metabolism system 
including drug-metabolizing enzymes, drug 
transporters, and drug-inducible ligand-
activated transcription factors (LATFs). 
Bilirubin is of clinical concern since severe 
neonatal jaundice may lead to “kernicterus” 
and neurotoxicity (Kapitulnik, 2004). 
Hyperbilirubinemia in the newborn is par-
ticularly a problem in preterm infants owing 
to more profound hemolysis, and immatu-
rity of liver function. However, bilirubin is 
also an interesting antioxidant which may 
attenuate atherosclerosis (Lin et al., 2008). 
Hence, bilirubin synthesis and its catabo-
lism has to be strictly controlled. The key 
to bilirubin’s elimination is glucuroni-
dation by UDP-glucuronosyltransferase 
UGT1A1. However, alternative pathways 
of bilirubin catabolism have also been 
observed. For example, the dioxin TCDD, 
a “classical” ligand of the Ah receptor 
(AhR) stimulates bilirubin elimination in 
congenitally jaundiced, UGT1A1-defective 
Gunn rats (Kapitulnik and Ostrow, 1977). 
Furthermore, bilirubin itself activates 
the AhR postnatally, leading to increased 
transcription of CYP1A1 and CYP1A2 in 
Gunn rats (Kapitulnik and Gonzalez, 1993). 
Bilirubin and its extrahepatically formed 
glucuronides are taken up from blood into 
hepatocytes by OATP1B1 and OATP1B3 
(Nies et al., 2008). Following conjugation 
bilirubin glucuronides are biliary secreted 
by ABCC2.
UGT1A1 and all the above transport-
ers are transcriptionally regulated by the 
constitutive androstane receptor CAR 
(Huang et al., 2003). In CAR-defective 
mice phenobarbital-mediated induction 
of these proteins is absent. When human 
CAR is transfected into CAR-null mice 
phenobarbital and bilirubin itself activate 
CAR, the latter finding suggesting homeo-
static control between enzyme substrate 
and activation of its major transcription 
factor. Bilirubin is a ligand of the AhR, a 
multifunctional transcription factor which 
induces a different set of genes than CAR 
in the drug metabolism system (Nguyen 
and Bradfield, 2008). It was discovered by 
the induction of aryl hydrocarbon metab-
olism and as mediator of dioxin toxicity. 
However, the AhR is also involved in devel-
opment, cell proliferation, differentiation, 
and immune biology. The importance of 
the AhR in UGT1A1 induction has been 
demonstrated in human hepatocyte cul-
tures treated with 3-methylcholanthrene 
(Ritter et al., 1999). Notably, phenobarbital 
and bilirubin are not ligands of CAR but 
activate CAR via phosphorylation/dephos-
phorylation pathways (Timsit and Negishi, 
2007). Binding sites for CAR and the AhR 
have been identified in a 290-bp cluster of 
the human UGT1A1, termed gtPBREM 
(phenobarbital responsive enhancer mod-
ule; Figure 1; Sugatani et al., 2005). The 
gtPBREM cluster contains binding sites for 
a number of ligand-activated transcrip-
tion factors including pregnane X recep-
tor (PXR), glucocorticoid receptors GR1 
and GR2, CAR, antioxidant-responsive 
Nrf2 (Yueh and Tukey, 2007), AhR, and 
fibrate-inducible peroxisome prolifera-
tor-activated receptor PPARα (Seneko-
Effenberger et al., 2007). It is important 
to note that the CAR binding site (gtNR1) 
plays a central role in UGT1A1 induction by 
both CAR and PXR, which is supported by 
site-directed mutagenesis and electropho-
retic mobility shift assays (Sugatani et al., 
2005). The cluster appears to be evolution-
ary conserved since the same arrangement 
of LATF-binding sites was found in the 
baboon (Caspersen et al., 2007). Allelic 
variants involved in bilirubin clearance 
have also been detected in the gtPBREM 
cluster. For example, the (TA)7 promoter 
polymorphism UGT1A1∗28, responsible 
for Gilbert’s syndrome, is often in linkage 
disequilibrium with the T3279G polymor-
phism in the gtPBREM cluster (Sugatani 
et al., 2008).
Perinatal UGt1a1 indUction
It is tempting to speculate that the gtP-
BREM cluster of UGT1A1 is related to 
perinatal UGT1A1 induction and bilirubin 
homeostasis in the adult (Bock and Köhle, 
2010; Bock, 2011). In perinatal stressful 
conditions glucocorticoids may be involved 
in UGT1A1 induction by CAR and PXR 
(Pascussi et al., 2008). In addition to CAR 
(Huang et al., 2003), activated PXR has also 
been demonstrated to induce UGT1A1 
and enhance bilirubin clearance (Xie et al., 
2003). With regard to AhR-mediated induc-
tion evidence was obtained that both AhR 
and Nrf2 are required for UGT induction 
(Yeager et al., 2009). Interestingly, CAR was 
found to be low in neonatal livers. Hence, 
the deficit of CAR activity may contribute 
to neonatal jaundice (Huang et al., 2003).
BilirUBin’s antioxidant fUnction
Ligand-activated transcription factors which 
bind in the distal gtPBREM cluster are 
operating in concert with other transcrip-
tion factors such as HNF1 and HNF4 and 
with multiple factors of the proximal pro-
moter. This is demonstrated by the (TA)7 
and T3279G polymorphisms which syner-
gistically reduce CAR- and AhR-mediated 
UGT1A1 induction not only in transfected 
cells (Sugatani et al., 2008) but also in human 
liver samples (Li et al., 2009). Decreased 
UGT1A1 expression leads to increased 
serum bilirubin which may contribute to 
bilirubin’s antioxidant function (Stocker 
et al., 1987a). Albumin-bound bilirubin or 
conjugated bilirubin have also been shown 
to exhibit antioxidant activity (Stocker 
et al., 1987b; Wu et al., 1996; Kapitulnik and 
Maines, 2009). Evidence was obtained that 
heme oxygenase/biliverdin reductase activ-
ity and biliverdin–bilirubin redox cycles are 
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essential for bilirubin’s antioxidant and local 
atheroprotective functions (Baranano et al., 
2002). The antioxidant action of bilirubin for 
lipids can be complementary to glutathione 
(Sedlak et al., 2009). Bilirubin may be partic-
ularly effective in reducing lipid peroxides as 
it easily enters the lipid environment (Zucker 
et al., 1999). However, bilirubin catabolism 
by hepatic UGT1A1 activity is also deci-
sive for bilirubin’s antioxidant function, as 
evidenced by many epidemiologic studies 
with UGT1A1∗28 homozygotes (Lin et al., 
2008; Bock and Köhle, 2010, for references). 
Notably, UGT1A1-regulating LATFs may be 
therapeutic targets (Kapitulnik and Maines, 
2009; Navarro et al., 2009). In conclusion, 
bilirubin has both neurotoxic and antioxi-
dant functions which are keeping clinicians 
and basic scientists busy.
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Figure 1 | Schematic illustration of allelic variants and the position of response elements binding 
ligand-activated transcription factors in the enhancer/promoter region of human ugT1A1. Positions 
are taken from Sugatani et al. (2005), and Bock and Köhle (2010). For discussion see text.
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